Pending Policies - Medicine


Urinary Metabolite Tests for Adherence to Direct-Acting Antiviral Medications for Hepatitis C

Number:MED207.156

Effective Date:11-15-2018

Coverage:

This medical policy has become inactive as of the end date above.  There is no current active version and is not to be used for current claims adjudication or business purposes.

*CAREFULLY CHECK STATE REGULATIONS AND/OR THE MEMBER CONTRACT*

Measurement of direct-acting antiviral drug metabolite levels for the purpose of monitoring adherence to treatment for hepatitis C infection is considered experimental, investigational and/or unproven.

Description:

Metabolites of some direct-acting antiviral (DAA) medications (e.g., sofosbuvir) can be measured in the urine. Measurement of urine drug levels reflects serum drug levels and thus has the potential for use as a test of adherence.

Background

While DAA medications have been a breakthrough treatment for chronic hepatitis C infection, they are also very costly. This produces a greater incentive to manage and monitor use to avoid prescribing in situations where they will be of no benefit. Maximizing adherence will ensure that the greatest amount of treatment benefit is achieved, and that the medications are being used in the most cost-effective manner.

Adherence to Treatment for Hepatitis C

Adherence to a full course of medication treatment is largely unknown for many of the newest DAA medications. However, data from adherence to other medications for hepatitis C infection suggest that it may be suboptimal on average. A prior Veteran’s Administration study on rates of discontinuation for interferon and ribavirin in patients with hepatitis C infection reported that 54.9% of all patients discontinued treatment early. (1) For the first-generation DAA boceprevir, Gordon et al. (2012) analyzed adherence in the SPRINT-2 and RESPOND-2 trials. (2) Adherence above 80% was reported for 63% of the treated patients in 1 trial and 71% in the other. For patients with adherence above 80%, the sustained virologic response (SVR) was 86% and 90% in the respective trials. By contrast, for patients with adherence below 80%, rates of SVR were 8% and 32%, respectively.

The newer DAA medications (e.g., sofosbuvir, simeprevir, ledipasvir) have greater efficacy, fewer adverse effects, and greater convenience than earlier agents. This would be expected to improve adherence; however, empirical data for this is lacking, particularly data on treatment in real-world settings.

Some literature on factors influencing adherence to hepatitis C treatment has been published, but most is prior to availability of DAAs. A 2014 systematic review analyzed 9 studies on factors influencing adherence. (3) Two factors had a significant negative association with adherence, psychiatric disorders, and higher doses of medications. In addition, female gender showed a trend toward a negative association. Human immunodeficiency virus (HIV) coinfection and hemoglobin level were positively associated with adherence. Another systematic review in 2013 evaluated adherence to treatment for hepatitis B and C infections, prior to availability of DAAs. (4) This review included 13 studies on hepatitis C. Mean adherence rates in these studies ranged from 27% to 97%, and the percentage of patients who had adherence rates above 80% ranged from 27% to 96%.

In addition to maximizing treatment success and cost-effectiveness, knowledge about treatment adherence can assist clinicians in managing treatment failures. Some patients will not achieve a sustained response, even with the newer agents with the greatest efficacy. In these patients, retreatment is an important consideration, and can be difficult. In deciding on retreatment, information that would indicate whether the failure is due to nonadherence or nonresponse to the medication is helpful in determining whether retreatment is indicated, and in determining which medication(s) should be used during retreatment.

Methods of Measuring Adherence

Various methods can be used to monitor adherence. Patient report is the most common and efficient method, but this is the most subjective and has been shown to overestimate adherence. (4) Pill count is another method, but is more cumbersome, and can be easily manipulated by patients. More sophisticated monitoring methods, such as sensors built into pill bottles, are expensive and usually reserved for research studies.

Measuring concentrations of medication in the serum or urine may be the most objective measure for evaluating adherence. This requires a blood or urine sample, and good benchmarks for levels that indicate optimal adherence. There is some ability to manipulate these results (i.e., if correct doses are taken near the time of measurement but not at other times), but this is more difficult than with other methods.

Regulatory Status

SOF-Adhere® (Precision Toxicology, San Diego, CA) is a commercially available assay for the presence of metabolites to sofosbuvir. The test is performed on a patient’s urine sample, and uses liquid chromatography mass spectrometry to measure drug levels. It is intended for use with patients who are being treated with sofosbuvir (Sovaldi®, Harvoni®) as an aid for determining adherence.

The Precision Toxicology website states that the SOF-Adhere® “also monitors for the presence and quantity of over 40 common prescription and illicit drugs that could potentially be contraindicated by the treatment plan.”

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Urine metabolite tests for adherence to antiviral medications for hepatitis C infection (e.g., SOF-Adhere®; Precision Toxicology) are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

Rationale:

This medical policy was created in January 2016, which included searches of the MedLine database. The most recent literature update was performed through September 27, 2018. The following is a summary of key literature.

Medical policies assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

Measurement of serum direct-acting antiviral (DAA) metabolites is best considered a potential component of a therapeutic intervention for hepatitis C infection, with the intent of improving treatment response by increasing adherence. The optimal study design for a therapeutic intervention is a randomized controlled trial (RCT) that includes clinically relevant measures of health outcomes. RCTs are particularly important when evaluating adherence because the multiple potential variables influencing adherence will be difficult to control for in nonrandomized studies.

A review of the MedLine database did not identify any published studies addressing the efficacy of measuring serum DAA metabolites to assess compliance. Several abstracts and meeting presentations, representing unpublished studies, were cited on the test developer’s website (Precision Toxicology).

RCTs are needed to evaluate the efficacy of measurement of serum DAA metabolites in monitoring adherence. These RCTs should compare treatment using urine monitoring for adherence with treatment not using urine monitoring (i.e., either a comparison with no adherence monitoring or a comparison with alternative methods of monitoring adherence). Outcomes of treatment should be, at minimum, adherence measured as rigorously as possible and/or treatment response.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in September 2018 revealed unpublished trials that might influence this policy as listed in Table 1.

Table 1: Ongoing, Unpublished Clinical Trials

NCT No.

Trial Name

Planned Enrollment

Completion Date

Ongoing

NCT03520660

Long-Term Follow-Up of Subjects with CHC who Achieved a Sustained Virological Response Following Therapy with Direct Acting Antiviral Agents

450

Dec 2032

Table Key:

NCT: national clinical trial;

CHC: chronic hepatitis C.

Practice Guidelines and Position Statements

Centers for Disease Control and Prevention (CDC) et al.

Current treatment recommendations for hepatitis C infection were created by the CDC in collaboration with the American Association for Study of Liver Diseases (AASLD), the Infectious Diseases Society of America, and the International Antiviral Society?USA. It provides up-to-date guidelines for the treatment of hepatitis C. (5) These guidelines mention adherence in the chapter “Monitoring Patients Who Are Starting Hepatitis C Treatment, Are on Treatment, or Have Completed Therapy.” This chapter was last updated in September 2016 and there is no mention of using serum drug metabolites to monitor adherence. The following recommendation is made: “Clinic visits or telephone contacts are recommended as clinically indicated during treatment to ensure medication adherence, and to monitor for adverse events and potential drug-drug interactions with newly prescribed medications.”

The CDC et al., rated this recommendation as a I (evidence and/or general agreement that a given diagnostic evaluation, procedure, or treatment is beneficial, useful, and effective), B (data derived from a single randomized trial, nonrandomized studies, or equivalent).

U.S. Department of Veterans Affairs (VA)

The VA updated its guidance on hepatitis C in 2016 in Chronic Hepatitis C Virus (HCV) Infection. (6) The following statement on adherence included: “Evaluating a patient’s potential adherence to medical recommendations and the prescribed regimen is crucial to the patient selection process. Factors that may complicate adherence, such as active substance abuse, depression, neurocognitive disorders, and lack of social support, should be adequately evaluated and addressed before initiating medications. Providers should incorporate strategies for measuring and supporting adherence within their clinics.”

The document does not provide further guidance on types of strategies for measuring and supporting adherence.

World Health Organization (WHO)

In April 2016, the WHO updated its guidelines on screening, care, and treatment for chronic hepatitis C infection. (7) The guidelines provide a framework for the frequency of monitoring patients undergoing hepatitis C virus treatment based on the type of regimen. Adherence should be monitored during the following weeks:

Direct-antiviral agent (DAA) alone: week 4;

DAA plus ribavirin: weeks 1, 2, 4, 8, and 12;

DAA plus pegylated interferon plus ribavirin: weeks 1, 2, 4, 8, and 12.

The document does not provide further guidance on how to monitor adherence.

Summary of Evidence

For individuals who have hepatitis C infection and are receiving treatment with direct-acting antiviral (DAA) medications who receive monitoring adherence to DAAs by measuring urinary metabolites, the evidence does not include published studies that evaluate the impact on adherence to DAA agents. Relevant outcomes are medication use. To demonstrate that such testing improves outcomes, randomized controlled trials are needed to assess treatment with and without measurement of DAA metabolites. Ideally, the outcome measures in these trials would be adherence to DAAs and sustained virologic response. The evidence is insufficient to determine the effects of the technology on health outcomes.

Contract:

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

Coding:

There is no specific CPT code to report this testing. It would likely be reported with a nonspecific definitive drug testing code (80375).

The therapeutic drug assay CPT codes would not be appropriate to report because they are not used for testing urine specimens.

CODING:

Disclaimer for coding information on Medical Policies

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT/HCPCS/ICD-9/ICD-10 Codes

The following codes may be applicable to this Medical policy and may not be all inclusive.

CPT Codes

80375

HCPCS Codes

None

ICD-9 Diagnosis Codes

Refer to the ICD-9-CM manual

ICD-9 Procedure Codes

Refer to the ICD-9-CM manual

ICD-10 Diagnosis Codes

Refer to the ICD-10-CM manual

ICD-10 Procedure Codes

Refer to the ICD-10-CM manual


Medicare Coverage:

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <http://www.cms.hhs.gov>.

References:

1. LaFleur J, Hoop R, Morgan T, et al. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res Notes. 2014; 7:266. PMID 24758162

2. Gordon SC, Yoshida EM, Lawitz EJ, et al. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther. Jul 2013; 38(1):16-27. PMID 23710734

3. Mathes T, Jaschinski T, Pieper D. Adherence influencing factors - a systematic review of systematic reviews. Arch Public Health. 2014; 72(1):37. PMID 25671110

4. Lieveld FI, van Vlerken LG, Siersema PD, et al. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol. May-Jun 2013; 12(3):380-91. PMID 23619254

5. AASLD – Recommendation for Testing, Managing, and Treating Hepatitis C (May 24, 2018). Prepared by American Association for Study of Liver Diseases. Available at <http://www.hcvguidelines.org> (accessed on September 26, 2018).

6. VA – Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations (August 27, 2018). Prepared by the Department of Veterans Affairs National Hepatitis C Resource Center and the Office of Public Health Available at <www.hepatitis.va.gov> (accessed on September 26, 2018).

7. WHO – World Heatlh Organization Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection (July 2018). Available at <http://apps.who.int> (accessed September 26, 2018).

8. Urinary Metabolite Tests for Adherence to Direct-Acting Antiviral Medications for Hepatitis C (Archived). Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (February 2017) Medicine 2.04.134.

Policy History:

Date Reason
9/14/2019 Document became inactive.
11/15/2018 Document updated with literature review. Coverage unchanged. Reference 7 was added.
2/15/2017 Reviewed. No changes.
6/1/2016 New medical document. Measurement of direct-acting antiviral drug metabolite levels for the purpose of monitoring adherence to treatment for hepatitis C infection is considered experimental, investigational and/or unproven.

Archived Document(s):

Back to Top